Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.67 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496398 | 0.89 | DNM1 (0.80) | DNM1BDKRB2TSHRALDH1A1TDP1 | |
| Bromide SCHEMBL126636 | 0.86 | DNM1 (0.81) | DNM1BDKRB2TSHRALDH1A1TDP1 | |
| Phosphine SCHEMBL31655327 | 0.86 | DNM1 (0.75) | DNM1BDKRB2TSHRALDH1A1TDP1 | |
| SCHEMBL30703682 | 0.86 | DNM1 (0.75) | DNM1BDKRB2TSHRALDH1A1TDP1 | |
| Bromide SCHEMBL302420 | 0.86 | DNM1 (0.81) | DNM1BDKRB2TSHRALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL23198627 | 0.86 | DNM1 (0.75) | DNM1BDKRB2TSHRALDH1A1TDP1 | |
| SCHEMBL9303471 | 0.86 | DNM1 (0.75) | DNM1BDKRB2TSHRALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL124627 | 0.86 | DNM1 (0.75) | DNM1BDKRB2TSHRALDH1A1TDP1 | |
| Iodide SCHEMBL187956 | 0.86 | DNM1 (0.75) | DNM1BDKRB2TSHRALDH1A1TDP1 | |
| SCHEMBL29769886 | 0.86 | DNM1 (0.75) | DNM1BDKRB2TSHRALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005005375-A1 | METHOD FOR PRODUCING 4-CYANO-3-HYDROXYBUTYRIC ACID ESTERS | LANXESS DEUTSCHLAND GMBH (DE) | 2005-01-20 | — | — | WO | claimed |
| WO-1995001962-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 3-(1-AMINO-1,1-BISALKYLMETHYL)-1-SUBSTITUTED-PYRROLIDINES | WARNER-LAMBERT COMPANY (US) | 1995-01-19 | — | — | WO | claimed |
| US-5347017-A | Process for chiral 3-(1-amino-1,1-bisalkylmethyl)-1-substituted-pyrrolidines | WARNER-LAMBERT COMPANY (US) | 1994-09-13 | — | — | US | claimed |
| EP-3604276-A1 | NEW COMPONENTS FOR ELECTROLYTE COMPOSITIONS | SOLVAY SA (BE) | 2020-02-05 | — | — | EP | disclosed |
| US-7423162-B2 | Process for the preparation of (4-hydroxy-6-oxo-tetrahydropyran-2-yl) acetonitrile and derivatives | DSM IP ASSETS B.V. (NL) | 2008-09-09 | — | — | US | disclosed |
| EP-1620423-B1 | PROCESS FOR THE PREPARATION OF (4-HYDROXY-6-OXO-TETRAHYDROPYRAN-2-YL) ACETONITRILE AND DERIVATIVES THEREOF | DSM IP ASSETS BV (NL) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007137816-A1 | PROCESS FOR THE PREPARATION OF EPOXIDE INTERMEDIATES FOR PHARMACEUTICAL COMPOUNDS SUCH AS STATINS | DSM IP ASSETS B.V. (NL) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007128469-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED NITRILES | DSM IP ASSETS B.V. (NL) | 2007-11-15 | — | — | WO | disclosed |
| US-20060258733-A1 | By reacting 2-(leaving group-methyl)-4-hydroxy-6-oxotetrahydropyran with a cyanide ion in water at a pH of 0-5; nitrile may be reduced to form an aminoethyl group; reacting with an acetal-forming agent to form a 1,3-dioxane derivative; may be further converted to atorvastatin or its calcium salt | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2006-11-16 | — | — | US | disclosed |
| EP-1620423-A1 | PROCESS FOR THE PREPARATION OF (4-HYDROXY-6-OXO-TETRAHYDROPYRAN-2-YL) ACETONITRILE AND DERIVATIVES THEREOF | DSM IP Assets B.V. (NL) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005005375-A1 | METHOD FOR PRODUCING 4-CYANO-3-HYDROXYBUTYRIC ACID ESTERS | LANXESS DEUTSCHLAND GMBH (DE) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004096788-A1 | PROCESS FOT THE PREPARATION OF (4-HYDROXY-6-OXO-TETRAHYDROPYRAN-2-YL) ACETONITRILE AND DERIVATIVES THEREOF | DSM IP ASSETS B.V. (NL) | 2004-11-11 | — | — | WO | disclosed |
| US-5466828-A | Chiral 3-cyano-1-substituted-pyrrolidines | WARNER-LAMBERT COMPANY (US) | 1995-11-14 | — | — | US | disclosed |
| WO-1995001962-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 3-(1-AMINO-1,1-BISALKYLMETHYL)-1-SUBSTITUTED-PYRROLIDINES | WARNER-LAMBERT COMPANY (US) | 1995-01-19 | — | — | WO | disclosed |
| US-5347017-A | Process for chiral 3-(1-amino-1,1-bisalkylmethyl)-1-substituted-pyrrolidines | WARNER-LAMBERT COMPANY (US) | 1994-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258733-A1 | By reacting 2-(leaving group-methyl)-4-hydroxy-6-oxotetrahydropyran with a cyanide ion in water at a pH of 0-5; nitrile may be reduced to form an aminoethyl group; reacting with an acetal-forming agent to form a 1,3-dioxane derivative; may be further converted to atorvastatin or its calcium salt | HMGCR, CYP11B2, CYP4F2 | DNM1 421/4885BDKRB2 3884/4885TSHR 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.